EA201992059A1 - PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL - Google Patents
PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVELInfo
- Publication number
- EA201992059A1 EA201992059A1 EA201992059A EA201992059A EA201992059A1 EA 201992059 A1 EA201992059 A1 EA 201992059A1 EA 201992059 A EA201992059 A EA 201992059A EA 201992059 A EA201992059 A EA 201992059A EA 201992059 A1 EA201992059 A1 EA 201992059A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- immunogenous
- peptides
- platform
- identification
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Настоящее изобретение относится к способам идентификации фрагментов полипептида, которые являются иммуногенными для конкретного субъекта-человека, способам получения фармацевтических композиций, содержащих такие полипептидные фрагменты, фармацевтическим композициям, содержащим такие полипептидные фрагменты, и способам лечения с использованием таких композиций. Способы включают идентификацию фрагмента полипептида, который связывается с множеством HLA отдельных субъектов.The present invention relates to methods for identifying fragments of a polypeptide that are immunogenic for a particular human subject, methods for producing pharmaceutical compositions containing such polypeptide fragments, pharmaceutical compositions containing such polypeptide fragments, and methods of treatment using such compositions. The methods include identifying a fragment of a polypeptide that binds to multiple HLAs of individual subjects.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1703809.2A GB201703809D0 (en) | 2017-03-09 | 2017-03-09 | Vaccine |
PCT/EP2018/055232 WO2018158457A1 (en) | 2017-03-03 | 2018-03-02 | Population-based immunogenic peptide identification platform |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992059A1 true EA201992059A1 (en) | 2020-03-31 |
Family
ID=58605461
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992057A EA201992057A1 (en) | 2017-03-09 | 2018-03-02 | PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE |
EA201992059A EA201992059A1 (en) | 2017-03-09 | 2018-03-02 | PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL |
EA201992058A EA201992058A1 (en) | 2017-03-09 | 2018-03-02 | VACCINE |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992057A EA201992057A1 (en) | 2017-03-09 | 2018-03-02 | PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992058A EA201992058A1 (en) | 2017-03-09 | 2018-03-02 | VACCINE |
Country Status (2)
Country | Link |
---|---|
EA (3) | EA201992057A1 (en) |
GB (1) | GB201703809D0 (en) |
-
2017
- 2017-03-09 GB GBGB1703809.2A patent/GB201703809D0/en not_active Ceased
-
2018
- 2018-03-02 EA EA201992057A patent/EA201992057A1/en unknown
- 2018-03-02 EA EA201992059A patent/EA201992059A1/en unknown
- 2018-03-02 EA EA201992058A patent/EA201992058A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201992057A1 (en) | 2020-03-06 |
GB201703809D0 (en) | 2017-04-26 |
EA201992058A1 (en) | 2020-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019010524A2 (en) | Population-based immunogenic peptide identification platform | |
CY1124867T1 (en) | SINGLE REGION ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS | |
EA201992063A1 (en) | BINDING ErbB-2 AND ErbB-3 SPECIFIC ANTIBODIES FOR USE FOR TREATMENT OF CELLS THAT CONTAIN THE NRG-1 FUSED GENE | |
PE20191081A1 (en) | NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USE THEM | |
EA201892548A1 (en) | ANTIBODIES TO ALPHA-SINUCULINE AND THEIR APPLICATION | |
EA201792573A1 (en) | TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION | |
EA201890640A1 (en) | RECOMBINANT VECTORS CONTAINING PEPTIDE 2A | |
EA201890145A1 (en) | ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | |
CY1124143T1 (en) | BONE MORPHOGENETIC PROTEINS | |
CY1125150T1 (en) | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | |
AR110114A1 (en) | ANTIBODIES AGAINST b-AMYLOID PIROGLUTAMATO AND ITS USES | |
CY1121734T1 (en) | MUTANT OspA FRAGMENTS AND METHODS AND USES THEREOF | |
EA201792561A1 (en) | ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION | |
EA201892225A1 (en) | ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION | |
MX2019003970A (en) | Immunogenic arginase peptides. | |
EA202091095A1 (en) | ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGUES | |
CY1126031T1 (en) | COMPOSITIONS FOR CLEANSING THE COLON AND TREATMENT OF GASTROINTESTINAL DISORDERS | |
MX2021007589A (en) | Anti-il-36 antibodies and methods of use thereof. | |
EA202190647A1 (en) | ANTIBODIES TO KLRG1 | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
EA202192488A1 (en) | ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS | |
CY1126054T1 (en) | PEPTIDES FOR THE TREATMENT AND PREVENTION OF DIABETES AND RELATED DISORDERS | |
MX2019013211A (en) | Anti-jagged1 antigen binding proteins. | |
EA202092281A1 (en) | ANTI-PfRH5 ANTIBODIES AND THEIR ANTIGEN-BINDING FRAGMENTS | |
EA201992059A1 (en) | PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL |